Should you buy DaVita stock now?
The technical signal for DaVita is currently NEUTRAL. DaVita trades at $179.39 as of 9/3/2026. The overall technical signal is: Hold. The technical analysis shows the following: MACD is negative (bearish trend) at -8.947 with rising momentum (signal: -10.438); RSI is at 37.3 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $218.43 points to 21.8% upside. This is a technical observation based on current data, not investment advice.
What is the price target for DaVita stock?
The average analyst price target for DaVita is $218.43. The current price is $179.39, which gives an upside of 21.8%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $196.59 and $240.27.
Is DaVita a dividend stock?
No, DaVita does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of DaVita stock?
DaVita is rated as a stock in the risk category Moderate. the annual standard deviation is 45.1%, which classifies the stock as Moderate.
Is DaVita overvalued?
No, DaVita is considered undervalued based on the analyst price target (21.8% upside). DaVita has the following valuation ratios: a P/E ratio of 14.9 (moderately valued), a P/S ratio of 0.8, a P/B ratio of 21.6. The analyst price target suggests that the stock is undervalued by 21.8%.
Is DaVita overbought?
No, DaVita is not overbought. RSI is at 37.3 (neutral zone). The technical indicators show: RSI is at 37.3 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 0.4% above the 20-day average (short-term uptrend). In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next DaVita earnings report?
The date of the next earnings report for DaVita has not been published yet. Check the company's investor calendar for updates.
Is DaVita shorted?
Yes, DaVita is shorted with 12.3% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying DaVita stock?
No, insiders are not buying DaVita shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 4 sales. On a net basis, 52,917,827 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 465,553,555 $ sold. Active sellers include BERKSHIRE HATHAWAY INC, Rodriguez Javier, Waters Kathleen Alyce and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is DaVita a good stock?
Based on our total score, DaVita is rated as a mediocre stock with a total score of 56 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 68/100, Quality: 65/100, Momentum: 34/100. In addition: analysts see 21.8% upside to the price target; technical signal: Hold. Whether DaVita is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for DaVita stock?
The outlook for DaVita based on current data: the average analyst price target is $218.43 (+21.8%); the P/E ratio is 14.9 (low – a possible value stock). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is DaVita stock moving?
DaVita is stable right now. The technical indicators show: the price is close to the 20-day average; short interest is 12.3% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can DaVita go?
The average analyst price target for DaVita is $218.43, which corresponds to a potential gain of 21.8% from the current price of $179.39. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can DaVita fall?
We lack enough history to give a specific floor for DaVita. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does DaVita do?
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, ... The company belongs to the Healthcare sector, more specifically the Medicinsk behandling industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate DaVita as an investment.
Did DaVita raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from DaVita. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is DaVita making money or losing money?
Yes, DaVita is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 6.1% — which is moderate. The operating margin (profit before interest and taxes) is 16.1%. At a P/E ratio of 14.9, you currently pay 14.9 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can DaVita go bankrupt?
The bankruptcy risk of DaVita is rated as moderate. Altman Z2 (a model for assessing financial distress) is 1.24 — that places the company in the middle zone. The Piotroski score (financial health 0-9, higher is better) is 7 — which is strong. Debt relative to equity is 727% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does DaVita have a lot of debt?
Yes, DaVita has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 727%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can DaVita service its debt? Can service its debt, but it weighs on the company — the interest coverage ratio (how many times earnings can cover interest payments) is 4.0x, and net debt equals 3.6 years of earnings (EBITDA).